Chemically Defined Stem Cell Differentiation for Endothelial Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human pluripotent-derived endothelial cells are hindered by the use of animal-derived reagents, leading to safety concerns, variability, and limited reproducibility, making them unsuitable for clinical applications and predictive analysis of toxic agents.
Innovation Solution
A method involving culturing human pluripotent stem cells in a chemically defined, serum-free medium with specific growth factors like BMP and Activin A, and without TGFβ1, to differentiate into endothelial cells, achieving high purity and consistency, and using inhibitors like SB431542 to modulate signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard protocols using animal-derived reagents are used, then endothelial cells can be generated, but safety concerns and variability increase
Solution Approach 1:
The patent removes animal-derived reagents (xenogeneic materials) from the culture medium, extracting the harmful components while retaining the essential function of supporting endothelial cell differentiation. This is achieved by using chemically defined, serum-free media that eliminates sources of variability and safety concerns associated with animal products.
Solution Approach 2:
The patent changes the chemical composition parameters of the culture medium by defining exact concentrations of growth factors (BMP4, Activin A, VEGF) and removing undefined animal-derived components. This parameter definition ensures batch-to-batch consistency and eliminates the variability inherent in serum-based systems.
2Productivity
If animal-derived reagents are used, then cell differentiation can proceed, but results become highly variable
Solution Approach 1:
The patent defines precise chemical parameters including specific concentrations of growth factors (BMP4 at 50 ng/mL, Activin A at 25 ng/mL, VEGF at 50 ng/mL) and maintains defined culture conditions throughout the differentiation process. This chemical definition eliminates the batch variability associated with animal-derived reagents while maintaining high differentiation efficiency.
Solution Approach 2:
The differentiation protocol is segmented into distinct stages with specific medium compositions for each phase: Stage 1 uses BMP4 and Activin A for mesoderm induction, Stage 2 adds VEGF and TGFβ inhibition for endothelial specification, and Stage 3 maintains endothelial cells in defined medium. This segmentation allows optimization of each stage while maintaining overall reproducibility.
3Reliability
If chemically defined serum-free medium is used, then safety and reproducibility improve, but differentiation efficiency must be maintained
Solution Approach 1:
The patent optimizes the concentrations of chemically defined growth factors to achieve both safety and efficiency: BMP4 (50 ng/mL) and Activin A (25 ng/mL) for mesoderm induction, followed by VEGF (50 ng/mL) for endothelial differentiation. These defined parameters ensure reproducible results while maintaining high differentiation efficiency comparable to or exceeding serum-based systems.
Solution Approach 2:
The patent uses small molecule inhibitors (SB431542 or A-83-01 at 5 μM) as intermediaries to block TGFβ signaling during endothelial differentiation. This intermediary approach fine-tunes the differentiation process by preventing unwanted TGFβ-mediated effects while allowing controlled endothelial specification, thereby maintaining high efficiency in chemically defined conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach generates endothelial cells that are xenogeneic material-free, highly reproducible, and clinically relevant, enabling efficient differentiation and expansion for therapeutic and modeling applications, while minimizing safety concerns associated with animal-derived materials.
Implementation Method 1
culturing the pluripotent stem cells for about two days in a chemically defined culture medium comprising a serum-free growth supplement, a Bone Morphogenetic Protein (BMP), and Activin A
Implementation Method 2
culturing the cultured cells of (i) for about three days in a chemically defined culture medium that comprises a serum-free growth supplement and does not comprise Transforming Growth Factor Beta 1 (TGFβ1)
Implementation Method 3
The culture medium of (ii) can comprise one or more factors selected from the group consisting of VEGF, BMP4, BMP2, BMP7, and an inhibitor of TGFβ1-mediated signaling
Implementation Method 4
The chemically defined culture medium of (i) further comprises a ROCK inhibitor. The ROCK inhibitor can be selected from the group consisting of Y27632 and Blebbistatin
Data Source
AI summary
The present invention relates to chemically defined and xenogeneic material-free methods for deriving endothelial cells from human pluripotent stem cells. In particular, the present invention provides highly efficient and reproducible methods of obtaining human endothelial cells from human pluripotent stem cells, where endothelial cells derived from the methods provided herein are suitable for clinically relevant therapeutic applications.